Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.33 USD
Change Today -0.01 / -0.43%
Volume 500.0
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

restorgenex corp (RESX) Snapshot

Open
$2.33
Previous Close
$2.34
Day High
$2.33
Day Low
$2.33
52 Week High
11/19/14 - $4.50
52 Week Low
05/29/15 - $2.33
Market Cap
43.4M
Average Volume 10 Days
1.9K
EPS TTM
$-0.68
Shares Outstanding
18.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESTORGENEX CORP (RESX)

Related News

No related news articles were found.

restorgenex corp (RESX) Related Businessweek News

No Related Businessweek News Found

restorgenex corp (RESX) Details

RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product is a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company’s pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. The company was formerly known as Stratus Media Group, Inc. and changed its name to RestorGenex Corporation in March 2014. RestorGenex Corporation is headquartered in Buffalo Grove, Illinois.

8 Employees
Last Reported Date: 04/3/15

restorgenex corp (RESX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $562.3K
Chief Financial Officer and Secretary
Total Annual Compensation: $287.7K
Senior Vice President of Clinical Development
Total Annual Compensation: $220.9K
Compensation as of Fiscal Year 2014.

restorgenex corp (RESX) Key Developments

RestorGenex Corporation Announces Data on the Effect of RES-529 in Pulmonary Fibrosis Models

RestorGenex Corporation announced the results from pre-clinical research evaluating RES-529, a small molecule that interferes with the molecular components which make up TORC1 and TORC2 protein complexes within the PI3K/Akt/mTOR pathway. The focus of the presentation was on in vitro and in vivo models of idiopathic pulmonary fibrosis (IPF). IPF is a disabling progressive and often deadly disorder with very few therapeutic options in which the lungs become progressively scarred over time causing shortness of breath, coughing, and limiting participation in everyday physical activities. Current treatments for IPF include oxygen therapy, pulmonary rehabilitation, and lung transplant. Median survival for IPF patients is only two to four years. The persistent activation of myofibroblasts has been described in IPF and signaling via the PI3K/Akt/mTOR pathway has been shown to mediate myofibroblast differentiation. These studies investigated the potential antifibrotic effect of RES-529 in TGF-β dependent activation of the PI3K/Akt/mTOR pathway, myofibroblast differentiation, and an in vivo pulmonary fibrosis model. RES-529 was shown to inhibit both mTOR-dependent signaling and myofibroblast differentiation in human lung fibroblasts. In a 10-day in vivo mouse model of bleomycin-induced pulmonary fibrosis, RES-529 showed a trend toward improved survival and less histologic fibrosis.

RestorGenex Corporation Announces Earnings Results for the First Quarter Ended March 31, 2015

RestorGenex Corporation announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company incurred a net loss of approximately $3.5 million, or $0.19 per share, for the first quarter ended March 31, 2015, compared to a net loss of $1.4 million, or $0.23 per share, for the same period in 2014. The increase in the net loss was due primarily to higher expenses associated with the company's core product development efforts.

Restorgenex Corporation Announces Resignation of Yael Schwartz as an Officer, Employee and Director

On April 30, 2015, RestorGenex Corporation entered into a resignation agreement with Yael Schwartz, Ph.D. pursuant to which Dr. Schwartz resigned as an officer, employee and director of RestorGenex and its subsidiaries.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RESX:US $2.33 USD -0.01

RESX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RESX.
View Industry Companies
 

Industry Analysis

RESX

Industry Average

Valuation RESX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESTORGENEX CORP, please visit www.restorgenex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.